- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02117336
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
A Phase I/Ib Study of P1446A-05 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth-Hitchcock Norris Cotton Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have histologically or flow cytometry confirmed diagnosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) according to the IWCLL 2008 criteria. The malignant B cells must co-express CD5 with CD19 or CD20. Patients who lack CD23 expression on their leukemia cells should be examined for (and found NOT to have) either t(11;14) or cyclin D1 overexpression, to rule out mantle cell lymphoma.
Active disease meeting at least 1 of the following IWCLL 2008 criteria for requiring treatment:
- A minimum of any one of the following constitutional symptoms:
Unintentional weight loss >10% within the previous 6 months prior to screening Extreme fatigue (unable to work or perform usual activities) Fevers of greater than 100.5ᵒF for ≥2 weeks without evidence of infection Night sweats without evidence of infection.
- Evidence of progressive marrow failure as manifested by the development of, or worsening of anemia or thrombocytopenia
- Massive (i.e., >6 cm below the left costal margin), progressive or symptomatic splenomegaly
- Massive nodes or clusters (i.e., >10 cm in longest diameter) or progressive lymphadenopathy
- Progressive lymphocytosis with an increase of >50% over a 2-month period, or an anticipated doubling time of less than 6 months
- Autoimmune anemia or thrombocytopenia that is poorly responsive to corticosteroids
Patients with relapsed/refractory CLL defined as having received ≥2 treatment regimens that included:
- A treatment regimen containing cytotoxic agents (eg, fludarabine, pentostatin, cladribine, cyclophosphamide, chlorambucil, bendamustine) AND
- A treatment regimen containing a therapeutic anti-CD20 antibody (e.g., rituximab, ofatumumab, obinutuzumab) AND
- A treatment regimen containing ibrutinib unless patient is not a candidate
- All treatment regimens must have been administered for ≥2 cycles unless patient is immediately allergic or intolerant to the regimen
- A disease expert at the study site must have a detailed discussion with the patient of other treatment options which either have been approved by the FDA or are part of or relevant to the standard care of patients with B-CLL/SLL in the multiply relapsed setting
- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Patients ≥18 year old
Patients must have organ function as defined below:
- Direct bilirubin ≤2 X institutional ULN (unless due to known Gilbert's syndrome or compensated hemolysis directly attributable to CLL)
- AST or ALT less than or equal to 2.5 X institutional ULN
- Creatinine ≤1.5 mg/dL OR estimated creatinine clearance ≥60 mL/min calculated using Cockcroft-Gault equation
- Total white blood cell count ≤200,000/mm3
- Platelets ≥10,000/mm3 with no active bleeding
- Ability to understand and the willingness to sign a written informed consent document
- Ability to swallow and retain oral medication
- Patients receiving chronic or acute warfarin treatment are not excluded, but should be monitored very closely or considered for switch to other therapies. P1446A-05 is both highly protein bound and a competitive inhibitor of CYP2C9 at higher concentrations and thus may potentiate the action of warfarin in patients
- Women of childbearing potential must have a negative serum β-human chorionic gonadotropin or urine pregnancy test at screening
- All patients of reproductive potential (heterosexually active men and women) must agree to a use of a barrier method of contraception and a second method of contraception and men must agree not to donate sperm during the study and for at least 4 weeks after receiving the last dose of study treatment
Exclusion Criteria:
- Recent therapeutic intervention including a) prior nitrosoureas or mitomycin C; prior radio- or toxin-immunoconjugates within 6 weeks; b) therapeutic anticancer antibodies (including rituximab, ofatumumab and obinituzumab) within 4 weeks; and c) all other chemotherapy or radiation therapy within 2 weeks prior to initiation of study drug
- The patient has not recovered from adverse events related to prior therapy to Grade ≤1 (excluding Grade 2 alopecia and neuropathy)
- Chronic use of corticosteroids in excess of prednisone 20 mg/day or its equivalent
- Patients who have been in the past enrolled on a study of a Cdk inhibitor
- History of prior malignancy except: a) Malignancy treated with curative intent and no known active disease present for ≥2 years prior to initiation of current study; b) adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; c) adequately treated in situ carcinomas (e.g., cervical, esophageal, breast, etc.) without evidence of disease; d) asymptomatic prostate cancer managed with "watch and wait" strategy; e) myelodysplastic syndrome which is clinically well controlled and no evidence of the cytogenetic abnormalities characteristic of myelodysplasia on the bone marrow at screening
- Patients with uncontrolled immune hemolysis or thrombocytopenia (positive direct antiglobulin test in absence of hemolysis is not an exclusion)
- Patients with known Richter's transformation which is progressive and is deemed to require immediate chemotherapy (history of Richter's transformation is not an exclusion); patients with prolymphocytic leukemia (prolymphocytes in blood >55%)
- Patients with clinically significant medical condition of malabsorption, inflammatory bowel disease, chronic conditions which manifest with diarrhea, refractory nausea, vomiting or any other condition that will interfere significantly with the absorption of study drugs
- Patients with mean QTc interval >450 msec at screening and patients taking drugs known to prolong the QTc interval (see Section 9, Appendix D) who cannot be switched to an alternative drug
- Nursing woman
- Known history of Human Immunodeficiency Virus (HIV) or active Hepatitis B or C. Intravenous immunoglobulin (IVIG) can cause a false positive hepatitis B serology. If patients receiving routine IVIG have core antibody or surface antigen positivity without evidence of active viremia (negative hepatitis B DNA) they may still participate in the study, but should have hepatitis serologies and Hepatitis B DNA monitored periodically by the treating physician.
- Any condition for which participation in the study is judged by the Investigator to be detrimental to the patient with inter-current illness including, but not limited to an uncontrolled active infection; unstable angina pectoris; uncontrolled cardiac arrhythmia; transient ischemic attack or pulmonary embolism during the previous 1 month or psychiatric/social situations that would jeopardize compliance with study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: P1446A-05
|
The study have dose escalation phase, followed by a dose extension phase.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose
Time Frame: Cycle 1 (Day 1 to 28 )
|
|
Cycle 1 (Day 1 to 28 )
|
Dose Limiting Toxicity
Time Frame: Cycle 1 (Day 1 to 28 )
|
To establish dose limiting toxicities (DLTs) of P1446A 05 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). - There will be two phase, a dose escalation phase, followed by a dose extension phase. |
Cycle 1 (Day 1 to 28 )
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response
Time Frame: At the end of every 2 cycles,Until disease progression or unacceptable toxicity (average of 2years)
|
|
At the end of every 2 cycles,Until disease progression or unacceptable toxicity (average of 2years)
|
Progression-free survival
Time Frame: At the end of every 2 cycles, until disease progression or unacceptable toxicity (average of 2years)
|
|
At the end of every 2 cycles, until disease progression or unacceptable toxicity (average of 2years)
|
Pharmacokinetic profile (Cmax,Tmax and AUC)
Time Frame: SD1, Cycle1-Cycle 5 (average of 5 month)
|
|
SD1, Cycle1-Cycle 5 (average of 5 month)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarker Analysis
Time Frame: Cycle1Day1, Cycle1Day28, Until disease progression or unacceptable toxicity (average of 2years)
|
To assess whether established (IGHV, p53 and Notch mutational status and ZAP70 and CD38 expression,) and exploratory biomarkers (e.g.
expression levels of Cyclin D1, p53 etc.) predict response to P1446A-05 in relapsed/refractory CLL
|
Cycle1Day1, Cycle1Day28, Until disease progression or unacceptable toxicity (average of 2years)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr Alexey V Danilov, MD, PhD, Dartmouth-Hitchcock Norris Cotton Cancer Centre
- Principal Investigator: Dr Jennifer R Brown, MD, PhD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P1446A-05/79/13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
-
Novartis PharmaceuticalsTerminatedRelapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Spain, United States
-
University of California, IrvineUnited States Department of DefenseActive, not recruitingAcute Myeloid Leukemia | Chronic Lymphocytic Leukemia | AML, Adult | CLL | CLL, Relapsed | CLL, RefractoryUnited States
-
AstraZenecaCLL ConsortiumCompletedB Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)United States
-
University Hospital, Clermont-FerrandRecruitingChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | CLL | Relapsed Chronic Lymphocytic Leukemia | Progressive Chronic Lymphocytic LeukemiaFrance
-
French Innovative Leukemia OrganisationBristol-Myers SquibbCompletedSmall Lymphocytic Leukemia | CLL, Relapsed | CLL, Refractory | Bruton Tyrosine Kinase InhibitorFrance
-
BeiGeneCompletedRelapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic LymphomaChina
-
Kite, A Gilead CompanyTerminatedRelapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic LymphomaUnited States, Italy
-
Allogene TherapeuticsRecruitingRelapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaUnited States, Spain, Canada, Australia, Italy
-
University Health Network, TorontoTakara Bio Inc.RecruitingRelapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell LymphomaCanada
Clinical Trials on P1446A-05
-
Piramal Enterprises LimitedCompleted
-
Piramal Enterprises LimitedCompletedSolid Tumor | Hematologic MalignancyIndia
-
Piramal Enterprises LimitedMelanoma Research Foundation Breakthrough ConsortiumSuspendedAdvanced or Inoperable Malignant Melanoma With BRAF MutationUnited States
-
Tarsus Pharmaceuticals, Inc.Completed
-
Tarsus Pharmaceuticals, Inc.Active, not recruitingHealthy VolunteerUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Cadila PharnmaceuticalsTerminatedStage III or Stage IV MelanomaUnited States
-
CuraGen CorporationCompleted
-
Meridigen Biotech Co., Ltd.Recruiting
-
Centrexion TherapeuticsCompletedOsteoarthritis, KneeUnited States